8.2 Clinical Pharmacokinetics: Dosing, Clearance, Vd, and TDM

Core Pharmacokinetic Parameters

Clinical pharmacokinetics involves the application of pharmacokinetic principles to the safe and effective therapeutic management of individual patients. The primary goals are enhancing efficacy and decreasing toxicity. The fundamental parameters are Volume of Distribution, Clearance, and Half-Life.

Volume of Distribution (Vd)

Volume of Distribution (Vd) is a theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma. It relates the amount of drug in the body (X) to the concentration of drug in the plasma (C).

• Equation: Vd = X / C
• Clinical Application (Loading Dose): Vd is primarily used to calculate the Loading Dose (LD) required to rapidly achieve a target therapeutic concentration (C_target).
• Loading Dose Equation: LD = (Vd * C_target) / (S * F)
  • Where S is the salt fraction (e.g., aminophylline is 0.8 or 80% theophylline) and F is bioavailability (F=1 for IV).
• Interpretation: A drug with a high Vd (e.g., digoxin, amiodarone, lipophilic drugs) extensively distributes into tissues, resulting in lower plasma concentrations. A drug with a low Vd (e.g., heparin, highly protein-bound drugs) remains primarily in the intravascular space.

Clearance (Cl)

Clearance (Cl) is the volume of plasma from which a drug is completely removed per unit of time (e.g., L/hr or mL/min). It is the single most important parameter determining maintenance dosing.

• Equation: Cl = Rate of Elimination / Plasma Concentration
• Clinical Application (Maintenance Dose): Clearance determines the maintenance dose (MD) required to maintain a steady-state target concentration (Css_target).
• Maintenance Dose Equation: MD rate = (Cl * Css_target) / (S * F)
• Total Clearance: Cl_total = Cl_renal + Cl_hepatic + Cl_other. Renal function (e.g., estimated creatinine clearance via Cockcroft-Gault) directly impacts the clearance of renally eliminated drugs (like vancomycin or aminoglycosides).

Half-Life (t1/2) and Steady State

Half-life is the time required for the plasma concentration to decrease by 50%. It depends on both Vd and Clearance.

• Equation: t1/2 = (0.693 * Vd) / Cl
• Steady State: Steady state is achieved when the rate of drug administration equals the rate of drug elimination. In first-order kinetics, it takes approximately 4 to 5 half-lives to reach steady state. Blood samples for Therapeutic Drug Monitoring (TDM) to assess maintenance dosing should ideally be drawn after steady state is reached.

Therapeutic Drug Monitoring (TDM)

TDM involves measuring drug concentrations in blood to optimize dosing, particularly for drugs with a narrow therapeutic index, significant interpatient pharmacokinetic variability, or a direct correlation between serum concentration and efficacy or toxicity.

Phenytoin

Phenytoin is unique because it follows Michaelis-Menten (non-linear or saturable) pharmacokinetics.

• At lower concentrations, elimination is first-order (proportional to concentration).
• As concentrations approach the therapeutic range (10-20 mcg/mL total, 1-2 mcg/mL free), hepatic enzymes become saturated. Elimination transitions to zero-order (constant amount eliminated per unit time).
• Clinical Consequence: Once enzymes are saturated, a small increase in dose can lead to a disproportionately large and potentially toxic increase in serum concentration. Doses must be adjusted cautiously (e.g., by 30-50 mg/day increments once >300mg/day).
• Correction for Hypoalbuminemia: Phenytoin is highly protein-bound (~90%). In patients with low albumin (< 3.2 g/dL) or renal failure, the measured total phenytoin level will falsely appear normal or low, while the active free fraction may be toxic.
• Winter-Tozer Equation: Corrected Phenytoin = Measured Total Phenytoin / ((0.2 * Albumin) + 0.1).

Vancomycin

Vancomycin is a glycopeptide antibiotic primarily used for MRSA infections. It requires TDM to ensure efficacy and prevent nephrotoxicity.

• Efficacy Target: The current consensus guidelines recommend targeting an Area Under the Curve to Minimum Inhibitory Concentration ratio (AUC24/MIC) of 400-600 mg*h/L for serious MRSA infections (assuming an MIC of 1 mg/L).
• Monitoring Methods: AUC-guided dosing is preferred over simple trough monitoring. This is typically achieved using Bayesian software programs (requiring 1 or 2 levels) or first-order pharmacokinetic equations using two specific steady-state levels (a peak and a trough).
• Toxicity: Trough concentrations > 15-20 mcg/mL are associated with an increased risk of nephrotoxicity.

Aminoglycosides (Gentamicin, Tobramycin, Amikacin)

Aminoglycosides are concentration-dependent bactericidal antibiotics. They exhibit post-antibiotic effect (PAE), meaning bacterial suppression continues even after levels fall below the MIC.

• Extended-Interval Dosing (EID): Also known as once-daily dosing (e.g., 5-7 mg/kg). This strategy maximizes the peak (optimizing bactericidal activity) while allowing a long drug-free period (trough < 1 mcg/mL) to minimize nephrotoxicity and ototoxicity. Monitoring often involves a single random level drawn 6-14 hours post-dose, evaluated using a nomogram (e.g., Hartford Nomogram).
• Traditional Dosing: Utilized when EID is contraindicated (e.g., pregnancy, ascites, severe burns, CrCl < 30 mL/min). Requires monitoring of Peaks (for efficacy, e.g., 5-10 mcg/mL for gent/tobra depending on infection severity) and Troughs (for toxicity, typically < 2 mcg/mL). Levels are drawn around the 3rd or 4th dose (at steady state).

Digoxin and Lithium

• Digoxin: Used for heart failure and atrial fibrillation rate control. It has a large Vd and a long distribution phase. Levels should be drawn at least 6-8 hours after a dose (preferably 12-24 hours) to allow for complete distribution; levels drawn too early will falsely appear high. Target range is typically 0.5-0.9 ng/mL for heart failure, higher for AFib.
• Lithium: Used for bipolar disorder. It is 100% renally eliminated. Levels are highly sensitive to sodium and fluid status (hyponatremia or dehydration increases lithium reabsorption in the kidney, leading to toxicity). Target steady-state trough levels are generally 0.6-1.2 mEq/L (drawn 12 hours post-dose).